Axovant Sciences Failed To Mention Critical Information [Seeking Alpha]
Axon Enterprise, Inc. (AXON)
Last axon enterprise, inc. earnings: 2/7 04:15 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.axovant.com/investors/sec-filings
Company Research
Source: Seeking Alpha
Summary Axovant Sciences licensed an unproven gene therapy from Benitec Biopharma. Toxicology, histology, and efficacy studies in sheep have not been announced. Axovant's Parkinson's gene therapy, AXO-Lenti-PD, has yet to enter clinical trials. The first generation Parkinson's gene therapy didn't produce meaningful results. Axovant announced a filing to sell $75 million in common shares. On July 10th 2018 Axovant Sciences ( AXON ) announced a partnership with Benitec Biopharma ( BNTC ) for exclusive global rights to BB-301, now named AXO-AAV-OPMD, for the treatment of oculopharyngeal muscular dystrophy, or OPMD, and five additional gene therapy programs in neurological disorders. Benitec will receive an upfront cash payment of $10 million and potentially an additional $17.5 million upon completion of four near-term milestones. Benitec is eligible to earn $187.5 million in total for other milestones, and retain 30% of the net profits on worldwide sales of AXO-
Show less
Read more
Impact Snapshot
Event Time:
AXON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AXON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AXON alerts
High impacting Axon Enterprise, Inc. news events
Weekly update
A roundup of the hottest topics
AXON
News
- Axon Enterprise (AXON) Stock Sinks As Market Gains: What You Should Know [Yahoo! Finance]Yahoo! Finance
- Why Is Axon (AXON) Up 2.1% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
- Global Swarm Intelligence Market Analysis Report 2024: Ant Colony Optimization Leads Market with 45.0% Share in 2023 - Forecast to 2030 for the $300+ Million Industry [Yahoo! Finance]Yahoo! Finance
- 25 US States with the Highest Number of Police Officers Per Capita [Yahoo! Finance]Yahoo! Finance
- Beyond The TASER: How Axon Is Revolutionizing Public Safety (And Your Portfolio) [Seeking Alpha]Seeking Alpha
AXON
Earnings
- 2/27/24 - Beat
AXON
Sec Filings
- 3/28/24 - Form 4
- 3/18/24 - Form PRE
- 3/18/24 - Form 4
- AXON's page on the SEC website